The role of glucocorticoids and corticotropin-releasing hormone regulation on anxiety symptoms and response to treatment

Greta B Raglan¹, Louis A Schmidt² and Jay Schulkin³,⁴

¹Department of Psychology, American University, Washington, District of Columbia, USA
²Department of Psychology, Neuroscience & Behavior, McMaster University, Hamilton, Ontario, Canada
³Department of Research, American College of Obstetricians and Gynecologists, Washington, District of Columbia, USA
⁴Department of Neuroscience, Georgetown University, Washington, District of Columbia, USA

Abstract

The stress response has been linked to the expression of anxiety and depression, but the mechanisms for these connections are under continued consideration. The activation and expression of glucocorticoids and CRH are variable and may hold important clues to individual experiences of mood disorders. This paper explores the interactions of glucocorticoids and CRH in the presentation of anxiety and depressive disorders in an effort to better describe their differing roles in each of these clinical presentations. In addition, it focuses on ways in which extra-hypothalamic glucocorticoids and CRH, often overlooked, may play important roles in the presentation of clinical disorders.

Introduction

Stress reactions are by no means universal, and the activation of ‘stress hormones’, such as glucocorticoids or corticotropin-releasing hormone (CRH), is not necessarily the mark of a stress response (1). Some individuals have lower-than-usual release of glucocorticoids in fearful situations, whereas others have higher release (2), and glucocorticoid release has differential effects and antecedents depending on an individual’s history and development (3, 4). The roles of these hormones are nonetheless crucial to our understanding of both resilience and pathology.

Glucocorticoid levels have been strongly linked to many pathological conditions (3). In particular, they have been strongly, and differentially, tied to generalized anxiety and depressive disorders, posttraumatic stress disorder (PTSD) and social anxiety. Each of these areas of research has implicated glucocorticoid levels, either high or low, in the presentation of variable symptoms of anxiety (3). Despite the seeming ties between these areas of research, little information exists to bridge the gap of understanding between the fields, and many discrepancies exist within each of the studies. It is important to note therefore that although each of these concerns focuses on the presentation of anxiety-like symptoms, the underlying glucocorticoid activities, as well as the presenting symptoms, are varied.

Although studies have reliably demonstrated the negative impacts of consistently high circulating glucocorticoids, high glucocorticoid levels by itself is not necessarily problematic. Rather, this may simply be an indicator of high energy and activity in some cases (3, 5). In some, this may reveal that the person is highly engaged in high-energy endeavors, whereas in others, it shows a potentially pathological response to stressors. Of particular concern are high levels of glucocorticoids with regulatory dysfunction such that the feedback system...
Glucocorticoids are responsible for upregulating CRH in the amygdala, frontal cortex, and bed nucleus of the stria terminalis (6, 7, 8, 9), whereas they down-regulate hypothalamic CRH (5). Given this site-specific relationship, it is possible that, when we observe glucocorticoid levels in a vacuum, we are actually looking at very different events with very different consequences due to the brain region upon which the glucocorticoids are acting (5, 10, 11). Levels of circulating CRH can have long-lasting expression independent of concurrent glucocorticoid levels. Both CRH levels and the site of activation, however, are important to the presentation of anxiety symptoms, such that noting CRH levels alone is also insufficient to understand the response (6).

By better understanding how glucocorticoid and CRH functioning in different contexts can lead to variable symptomatology, researchers may be better equipped to develop treatment strategies involving glucocorticoids for generalized anxiety and depressive disorders, PTSD, social anxiety and other conditions. The purpose of this paper is to explore the interactions of glucocorticoids and CRH in the presentation of anxiety and depressive disorders in an effort to better describe their differing roles in each of these clinical presentations. In addition, we describe ways in which extra-hypothalamic glucocorticoids and CRH, often overlooked, may play important roles in the presentation of clinical disorders.

Depression and anxiety

Although diagnostic criteria for anxiety and depressive disorders such as generalized anxiety disorder and major depressive disorder are unique and diverse, they are generally typified by heightened negative affect (or lowered positive affect), vegetative symptoms (e.g., sleep changes, appetite/weight changes) and thoughts that are hard to control (e.g., rumination, worry, guilt) (12). Underlying mechanisms for anxiety and depressive disorders may be similar, as evidenced by overlapping symptoms (e.g., irritability, high negative affect) and treatments (e.g., selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy) (3). Depression and anxiety can be temporary states based on an individual’s adjustment to a life circumstance, but often occur chronically over a person’s lifetime. These disorders can significantly inhibit functioning, and major depression itself has been linked to significantly reduced well-being and productivity (e.g., Stewart et al. 2003) (13).

Symptoms of anxiety and depressive disorders have been linked to hypersecretion of corticotropin-releasing hormone (CRH), leading to high levels of circulating glucocorticoids (5, 14, 15). This is supported by the fact that individuals with depression have increased startle response and may have enhanced anxious anticipation (16). In addition, some forms of psychosis such as schizophrenia and delusional disorders are associated with higher circulating glucocorticoids and high levels of CRH. Risks of developing symptoms of anxiety, mania and psychosis are also higher among individuals who have been prescribed glucocorticoid medications (17). Some have suggested that the link between glucocorticoids and depression may stem from overexposure to glucocorticoids early in life, for example, due to exposure to chronic stress (e.g., abuse) and the subsequent reduction of synaptic potentiation (10, 18). This overexposure may lead to a hyper-anxious state, producing vulnerability to exhaustion and possible depression (19). Certain CRH receptors such as CRH1 may also be linked to the development of depression after early stressful experiences (20), but trials with CRH1 antagonists are few, and findings do not strongly support their efficacy (21, 22).

Given the findings suggesting a link between high glucocorticoids and symptoms of mental illness, it is not surprising that inhibitors of glucocorticoids have been studied as a possible intervention for mental illness including depression. Although further study is necessary, it appears that corticosteroid synthesis inhibitors (CSIs) may show some efficacy in treating individuals with intractable depression (23). Kling and coworkers (23) propose that the mechanism of action is through a reduction in the expression of extra-hypothalamic CRH, rather than in a decrease in corticosteroids themselves (24). To achieve this, CSIs may reduce glucocorticoid enhancement of CRH in extra-hypothalamic regions (23). It has been postulated that these treatments may be best used as adjunctive treatments and have shown some success in studies (21). Interestingly, at least one case has been reported in which the administration of a corticosteroid (prednisone) reduced depression symptoms (24).

Ruthenium (Ru) compounds block glucocorticoids generally. Some studies have looked into giving Ru compounds to mental health patients to reduce glucocorticoid expression with the idea that high glucocorticoids were driving symptom expression.
Ru compounds such as mifepristone (RU486) have been shown to have efficacy in reducing psychotic symptoms in individuals with psychotic depression, though they may not be effective in reducing depression symptoms themselves (22).

**Posttraumatic stress disorder**

Posttraumatic stress disorder (PTSD) has been classified as an anxiety disorder and occurs in individuals who have been exposed to a traumatic event or events. This exposure can be a direct experience (e.g., experiencing or witnessing an event), by proxy (e.g., the event happens to a close friend or family member), or may be characterized by repeated exposure to the details through images or other means (25). PTSD is characterized by re-experiencing (e.g., nightmares, flashbacks), avoidance (i.e., of situations that may elicit memories), negative cognitions and mood (e.g., depression, anxiety), and arousal (e.g., hyper-responsiveness to stressors) (12). Symptoms of PTSD can present along a spectrum of severity and can have long-lasting effects. Although PTSD is often linked to military or combat situations, traumatic events occur in a range of circumstances and situations and may affect anyone (25).

In a phenomenon originally described by Mason and coworkers, individuals with PTSD surprisingly tend to have lower glucocorticoid levels than people without PTSD (Table 1) (26). This finding was initially controversial, given the seemingly strong link between glucocorticoid levels and high anxiety. Despite this, individuals with PTSD also have higher levels of CRH in the cerebral spinal fluid (27) and appear to have similar cortisol reactivity to individuals without the disorder (28). Based on these findings, it is apparent that multiple processes must be at play in order for opposing glucocorticoid profiles to create symptoms that appear, on the surface, to be similar. Several studies have shown that low levels of glucocorticoids are particularly prevalent among individuals with PTSD who have also experienced early life stressors such as long-term abuse or complex trauma. This indicates that a lifetime of adversity can lead to blunted stress reactivity, and can reduce the effectiveness of the stress response system.

In several studies of specific groups (e.g., Holocaust survivors, rape survivors), individuals who experience symptoms of PTSD have lower glucocorticoid levels than individuals without PTSD (29). This has led to the theory that the symptoms of PTSD may be treatable through infusions of glucocorticoids, particularly temporally with the traumatic event. Findings for this research, however, have been mixed.

| PTSD publications | Main findings related to glucocorticoids |
|-------------------|----------------------------------------|
| Mason et al. (1986) (26) | Shows lower cort levels in patients with PTSD |
| Mason et al. (1988) (44) | Shows lower glucocorticoid levels in patients with PTSD |
| Yehuda et al. (1990) (29) | Low urinary glucocorticoid levels in individuals with PTSD |
| Yehuda et al. (1995) (45) | Shows lower glucocorticoid levels in Holocaust survivors with PTSD |
| Yehuda et al. (2000) (46) | Shows that offspring of individuals with PTSD are also at increased risk for PTSD and have low glucocorticoid levels |
| Yehuda et al. (2002) (47) | Shows that lower glucocorticoid levels are associated with more severe PTSD symptoms |
| Glover & Poland (2002) (48) | Shows lower glucocorticoid levels in mothers with PTSD |
| Yehuda et al. (2005) (49) | Shows lower glucocorticoid levels of women with PTSD exposed to trauma during pregnancy, and in their children |
| Neylan et al. (2005) (50) | Shows that lower basal glucocorticoid levels predict severity of PTSD symptoms in police officers |
| Wessa et al. (2006) (51) | Shows lower glucocorticoid levels in patients with PTSD |
| Meewisse et al. (2007) (52) | Review showing low glucocorticoid levels in adults with PTSD |
| Yehuda et al. (2007) (53) | Shows that offspring of individuals with PTSD are also at increased risk for PTSD and have low glucocorticoid levels |
| Gill et al. (2008) (54) | Low glucocorticoid levels in women with PTSD |

PTSD, posttraumatic stress disorder.
dosed appropriately, may help to reduce the presentation of anxiety symptoms after individuals experience trauma.

It should be noted that medically prescribed glucocorticoids are not without risks. Treatment with glucocorticoids can have significant and long-lasting physical and psychological impacts on patients and has been reported to lead to debilitating psychological conditions in some cases (17). Several studies have found, however, that treatment with low doses of glucocorticoids can reduce symptoms of PTSD and particularly avoidance symptoms, as well as improving symptoms of specific phobias (32). These findings indicate that glucocorticoids at an appropriate level may be crucial to the formation and integration of memories related to traumatic events. Based on these findings, glucocorticoids may be a helpful intervention, but must be treated with some caution and may not be appropriate for the treatment of all individuals with risk factors for PTSD.

Social anxiety

Social anxiety is a biological phenomenon with underlying environmental influences, similar to PTSD or anxiety and depression. Correlates of social anxiety have been studied in macaques showing that temperament influences how individuals respond to the presence of stressors (34). Individuals with social anxiety may be framed as suffering from an acute version of a common state in children called shyness. Social anxiety, or the fear of judgement from others in social situations, may result in avoidant behaviors, heightened anxiety responses and potentially panic-like symptoms (35). Adults with social anxiety are more likely than non-socially-anxious adults to have been ‘shy’ as children (36), and exhibit many similar behavioral patterns including withdrawal and avoidance (36).

Although shy and fearful children tend to have high cortisol levels and high reactivity to stress when they are young (Fig. 1) (37, 38, 39), in later life, socially anxious individuals may develop a different pattern with reduced glucocorticoid levels and decreased reactivity (Figs 2 and 3) (40). As adolescents and adults, these children enter a hypoarousal phase, notable due to ‘shutting down’. This hypoarousal phase is marked by decreased energy, decreased reported anxiety, and reduced glucocorticoid levels (40). This could be an expression of a sort of learned hopelessness resulting in declining glucocorticoid expression.

This pattern of low glucocorticoids is similar to that seen among individuals with PTSD and may indicate a similar behavioral pattern related to avoidance. Also similar to individuals with PTSD, low doses of glucocorticoids administered during exposure for social anxiety have been shown to decrease the anxiety response (32). Studies indicate that chronic social stress, such as that which a shy or fearful child might experience, influences
Glucocorticoids, CRH and anxiety

G B Raglan et al.

Glucocorticoids are not just related to stress, but rather to energy levels as well. Accordingly, it is not just the presence or the absence of glucocorticoids that is important, but rather the ability to appropriately regulate these chemicals in a changing environment. This seems to be part of the key to resilience and overall health (1). In addition, the complex relationship between glucocorticoids and the experience of anxiety indicates that therapy to either reduce or increase glucocorticoid levels may be important in the treatment of various conditions including depression/anxiety, PTSD and social anxiety (Table 2). Additional research is needed in the area of how psychotherapy and other alternative treatments may affect glucocorticoid levels and change patterns of reactivity.

Glucocorticoids importantly influence the expression of CRH such that high glucocorticoids and high CRH are present in trait fearfulness. This raises the question, however, of what would happen, and whether it is possible, in the case of high glucocorticoids and low CRH. Could this potentially be a protective hormonal milieu that might reduce the expression of deleterious anxiety responses? Further, it is important to understand the complex relationship between glucocorticoids and CRH as they relate to the symptoms experienced by individuals with anxiety or depression, PTSD and social anxiety. These interactions may help to understand the differential expression of symptoms, as well as the underlying chemical influences. Glucocorticoids and CRH influence each other, as well as fear and anxiety responses, in different ways depending on their location and levels. The interactions of these two systems and others contribute to the presentation of symptomatology in several conditions and may also lead to a reduction in the body’s abilities to cope with stressful situations (1, 43).

As noted, CRH is differentially expressed throughout the brain. Differential expression of brain circuits such as in the amygdala may lead to differential expression of cortisol and CRH or may contribute to anxiety symptoms being expressed differently. Placental CRH is also being explored as a possible source of predispositions toward anxiety symptoms and high levels of circulating glucocorticoids. Fundamentally, the impact of glucocorticoids is to affect how a person responds to adversity over a lifetime, and it is within that frame that we may begin to target important areas for the treatment of anxiety conditions using novel glucocorticoid therapies in conjunction with more traditional medicines and therapies.

The literatures addressing each of these disorders, glucocorticoids and CRH are each vast in and of themselves. It is beyond the scope of this paper to comprehensively review each of these areas of work. The aim of this paper is rather to suggest that glucocorticoids and CRH, including within and outside of the HPA axis, are vital to the presentation of a variety of symptom profiles that differ based on localization of activation among other factors. In doing so, many valuable, relevant, and important studies may have been neglected, but the hope is that this

Table 2  Three clinical conditions and their relative levels of CRH and glucocorticoids.

| Anxiety/depression | Posttraumatic stress disorder | Social anxiety |
|--------------------|-------------------------------|---------------|
| High CRH High circulating glucocorticoids | High CRH Low circulating glucocorticoids | High CRH High circulating glucocorticoids when young; low levels when older |

Figure 3
Three-day average of daily salivary cortisol output from awakening until bedtime in shy and non-shy young adults. Reprinted from Personality and Individual Differences, Vol 55/6, Beaton EA, Schmidt LA, Schulkin J & Hall GB, Repeated measurement of salivary cortisol within and across days among shy young adults, Pages 705–710, Copyright (2013), with permission from Elsevier.

Table 2:
Three clinical conditions and their relative levels of CRH and glucocorticoids.
paper will spur others to action and encourage further research in these areas.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement
Greta Raglan was the primary author of this manuscript. She reviewed and edited the manuscript and approved the final version. Louis A Schmidt contributed to the writing, formatting and organization of this work. He reviewed and edited the manuscript and approved the final version. Jay Schulkin assisted in the conception and writing of this project. He reviewed and edited the manuscript and approved the final version.

References
1 McEwen BS, Gray JD & Nasca C. Recognizing resilience: learning from the effects of stress on the brain. Neurobiology of Stress 2014 1 1–11. (doi:10.1016/j.neus.2014.09.001)
2 Mujica-Parodi LR, Carlson JM, Cha J & Rubin D. The fine line between 'brave' and 'reckless': amygdala reactivity and regulation predict recognition of risk. Neuroimage 2014 103 1–9. (doi:10.1016/j.neuroimage.2014.08.038)
3 Sapolsky RM. Why Zebras Don't Get Ulcers, edn. 3. New York, NY, USA: Holt Paperbacks, 2004.
4 Gee DG, Babard-Durnam L, Telzer EH, Humphreys KL, Goff B, Shapiro M, Flannery J, Lumian DS, Farei DS, Caldera C, et al. Maternal buffering of human amygdala-prefrontal circuitry during childhood but not during adolescence. Psychological Science 2014 25 2067–2078. (doi:10.1177/0956797614550878)
5 Schulkin J. Evolutionary conservation of glucocorticoids and corticotropin releasing hormone: behavioral and physiological adaptations. Brain Research 2011 1392 27–46. (doi:10.1016/j.brainsci.2011.03.055)
6 Gouezely SL, Swanson AM, Jacobs AM, Howell JL, Mo M, DiLeone RJ, Koleske AJ & Taylor JR. Action control is mediated by prefrontal BDNF and glucocorticoid receptor binding. PNAS 2012 109 20714–20719. (doi:10.1073/pnas.1208342109)
7 Schulkin J, Morgan MA & Rosen JB. A neuroendocrine mechanism for sustaining fear. Trends in Neuroscience 2005 28 629–635. (doi:10.1016/j.tins.2005.09.009)
8 Dabrowska J, Hazra R, Guo J, DeVitt S & Rainnie DG. Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paracentral hypothalamus and the bed nucleus of the stria terminalis. Frontiers in Neuroscience 2013 7 1–14. (doi:10.3389/fnins.2013.00156)
9 Daniel SE & Rainnie DG. Stress modulation of opposing circuits in the bed nucleus of the stria terminalis. Neuropsychopharmacology 2016 41 103–125. (doi:10.1038/npp.2015.178)
10 Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. American Journal of Psychiatry 2004 161 195–216. (doi:10.1176/appi.ajp.161.2.195)
11 Sassi H, Fromont-Racine M, Grange T & Picet R. Tissue specificity of a glucocorticoid-dependent enhancer in transgenic mice. PNAS 1995 92 797–7201. (doi:10.1073/pnas.92.16.7197)
12 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, edn. 5. Arlington, VA, USA: American Psychiatric Association, 2013.
13 Stewart WF, Ricci JA, Chee E, Hahn SR & Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003 289 3135–3144. (doi:10.1001/jama.289.23.3135)
14 Gold PW & Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry 2002 7 254–275. (doi:10.1038/sj.mp.4001032)
15 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research 1999 33 181–214. (doi:10.1016/S0022-3956(98)00056-5)
16 Grillon C, Franco-Chaves JA, Mateus CF, Ionescu DF & Zarate CA. Major depression is not associated with blunting of aversive responses; evidence for enhanced anxious anticipation. PLoS ONE 2013 8 e70969. (doi:10.1371/journal.pone.0070969)
17 Judd LL, Schettler PJ, Brown ES, Wolkwitz OM, Sternberg EM, Bender BG, Bulloch K, Cudjow JS, deKloet ER, Fardet L, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. American Journal of Medicine 2014 171 1045–1051. (doi:10.1161/ajp.114.20191264)
18 Joëls M, Sarbadjutsingh RA & Karst H. Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacology Review 2012 64 901–938. (doi:10.1174/pr.112.015892)
19 Raglan GB & Schulkin J. Introduction to allostatics and allostatic load. In The Resilience Handbook: Approaches to Stress and Trauma, pp 44–56. Eds M Kent, MC Davis & JW Reich. London, UK: Routledge, 2013.
20 Kranzler HR, Fein R, Nelson EC, Covault J, Anton RF, Farrer L & Gelernter J. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011 156 960–968. (doi:10.1002/ajmg.b.31243)
21 Block SG & Nemeroff CB. Emerging antidepressants to treat major depressive disorder. Asian Journal of Psychiatry 2014 12 7–16. (doi:10.1016/j.ajp.2014.09.001)
22 Joffe RT. Hormone treatment of depression. Dialogues in Clinical Neuroscience 2011 13 127–138.
23 Kling MA, Coleman VH & Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depression and Anxiety 2009 26 641–649. (doi:10.1002/da.20546)
24 Vidal E, Stewart JT & Catalano G. A case of corticosteroid-responsive depression. Psychosomatics 2013 54 395–397. (doi:10.1016/j.psymp.2013.01.004)
25 Greenberg N, Brooks S & Dunn R. Latest developments in post-traumatic stress disorder: diagnosis and treatment. British Medical Bulletin 2015 114 147–155. (doi:10.1093/bmb/ldv014)
26 Mason JW, Gilder EL, Kosten TR, Ostroff RB & Podd L. Urinary free-cortisol levels in posttraumatic stress disorder patients. Journal of Nervous and Mental Disease 1986 174 145–149. (doi:10.1097/00005053-198603000-00003)
27 Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB & Charney DS. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. American Journal of Psychiatry 1997 154 624–629. (doi:10.1176/ajp.154.5.624)
28 Bremner JD, Vythilingam M, Vertemeten E, Adil J, Khan S, Nazeer A, Azal N, McGlashan T, Elzenga B, Anderson GM, et al. Cortisol response to a cognitive stress challenge in posttraumatic stress disorder (PTSD) related to childhood abuse. Psychoneuroendocrinology 2003 28 733–750. (doi:10.1016/s0306-4530(02)00067-7)

29 Yehuda R, Southwick S, Nussbaum G, Wahby V, Giller EL Jr & Mason JW. Low urinary cortisol excretion in patients with posttraumatic stress disorder. Journal of Nervous and Mental Disease 1990 178 366–369. (doi:10.1097/000553-199006000-00004)

30 Cohen H, Benjamini J, Kaplan Z & Kotler M. Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. European Neurpsychopharmacology 2000 10 429–433. (doi:10.1016/s0924-977x(00)00105-x)

31 Schelling G, Roozenendaal B & De Quervain DJF. Can posttraumatic stress disorder be prevented with glucocorticoids? Annals of the New York Academy of Science 2004 1032 158–166. (doi:10.1196/annals.1314.013)

32 De Quervain DJF & Margraf J. Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: a novel therapeutic approach. European Journal of Pharmacology 2008 571 156–165. (doi:10.1016/j.ejphar.2007.11.068)

33 Suris A, North C, Adinoff B, Powell CM & Greene R. Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Annals of Clinical Psychiatry 2010 22 274–279.

34 Rogers J, Shelton SE, Shelledy W, Garcia R & Kalin NH. Genetic influences on behavioral inhibition and anxiety in juvenile rhesus macaques. Genes Brain and Behavior 2006 5 127–140. (doi:10.1111/j.1601-183X.2006.00081.x)

35 Goodwin RD, Lieb R, Hoelfer M, Pfister H, Bittner A, Beeds K & Wittchen H. Panic attack as a risk factor for severe psychopathology. American Journal of Psychiatry 2004 161 2207–2214. (doi:10.1176/appi.ajp.2004.04020076)

36 Beidel DC & Turner SM. Shy Children, Phobic Adults: Nature and Treatment of Social Anxiety Disorder, 2nd ed. Washington DC, USA: American Psychological Association, 2007.

37 Russ SJ, Herbert J, Cooper P, Gunnar MR, Goodyer I, Croudace T & Murry L. Cortisol levels in response to starting school in children. Developmental Psychobiology 2010 54 1217–1228. (doi:10.1002/dev.20372)

38 Schmidt LA, Fox NA, Rubin KH, Sternberg EM, Gold PW, Smith CC & Schulkin J. Behavioral and neuroendocrine responses in shy typically developing 10 year-old children. Developmental Psychobiology 2012 57 306–314. (doi:10.1002/dev.20371)

39 Schmidt LA, Santesso DI, Schulkin J & Segalowitz SJ. Shyness is a necessary but not sufficient condition for high salivary cortisol in typically developing 10-year-old children. Personality and Individual Differences 2007 43 1541–1551. (doi:10.1016/j.paid.2007.04.011)

40 Beaton EA, Schmidt LA, Ashbaugh AR, Santesso DI, Antony MM & McCabe RE. Low salivary cortisol levels among socially anxious young adults: preliminary evidence from a selected and a non-selected sample. Personality and Individual Differences 2006 41 1217–1228. (doi:10.1016/j.paid.2006.02.020)

41 Albeck DS, McKittrick CR, Blanchard DC, Blanchard RJ, Nikulina J, McEwen BS & Sakai RR. Chronic social stress alters levels of corticotropin-releasing factor and arginine vasopressin mRNA in rat brain. Journal of Neuroscience 1997 17 4895–4903.

42 Erickson K, Drevets W & Schulkin J. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neuroscience and Biobehavioral Reviews 2003 27 233–246. (doi:10.1016/s0149-7640(03)00034-3)

43 Schulkin J, Gold PW & McEwen BS. Induction of corticotrophin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 1998 23 219–243. (doi:10.1016/s0305-0488(97)00099-1)

44 Mason JW, Giller EL, Kosten TR & Harkness L. Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder. Journal of Nervous & Mental Disease 1988 176 498–502. (doi:10.1097/000553-198808000-00008)

45 Yehuda R, Kahana B, Binder-Brynes K, Southwick SM, Mason JW & Giller EL. Low urinary cortisol excretion in Holocaust survivors with posttraumatic stress disorder. American Journal of Psychiatry 1995 152 982–986. (doi:10.1176/ajp.152.7.982)

46 Yehuda R, Bierer LM, Schmeidler J, Afefait DH, Breslau I & Dolan S. Low cortisol and risk for PTSD in adult offspring of Holocaust survivors. American Journal of Psychiatry 2000 157 1252–1259. (doi:10.1176/appi.ajp.157.8.1252)

47 Yehuda R, Hilligan SJ & Bierer LM. Cortisol level in adult offspring of Holocaust survivors: relation to PTSD symptom severity in the parent and child. Psychoneuroendocrinology 2002 27 171–180. (doi:10.1016/s0306-4530(01)00043-9)

48 Glover DA & Poland RE. Urinary cortisol and catecholamines in mothers of child cancer survivors with and without PTSD. Psychoneuroendocrinology 2002 27 805–819. (doi:10.1016/s0306-4530(01)00081-6)

49 Yehuda R, Engel SM, Brand SR, Seckle H, Marcus SM & Berkowitz GS. Transgenerational effects of posttraumatic stress disorder in babies of mothers exposed to the World Trade Center attacks during pregnancy. Journal of Clinical Endocrinology & Metabolism 2005 90 4115–4118. (doi:10.1210/jc.2005-0550)

50 Neylan TC, Brunet A, Pole N, Best SR, Metzler TJ, Yehuda R & Marmar CR. PTSD symptoms predict waking salivary cortisol levels in police officers. Psychoneuroendocrinology 2005 30 373–381. (doi:10.1016/j.psyneuen.2004.10.005)

51 Wessa M, Rohleder N, Kirschbaum C & Flor H. Altered cortisol awakening response in posttraumatic stress disorder. Psychoneuroendocrinology 2006 31 209–215. (doi:10.1016/j.psyneuen.2005.06.010)

52 Meewisse M, Reitsma JB, de Vries G, Gersons BPR & Olff M. Cortisol and post-traumatic stress disorder in adults. British Journal of Psychiatry 2007 191 387–392. (doi:10.1192/bjp.bp.106.024877)

53 Yehuda R, Teicher MH, Seckel JR, Grossman RA, Morris A & Bierer LM. Parental posttraumatic stress disorder as a vulnerability factor for low cortisol trait in offspring of Holocaust survivors. Archives of General Psychiatry 2007 64 1040–1048. (doi:10.1001/archpsyc.64.9.1040)

54 Gill J, Vythilingam M & Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-α, and IL-6 in women with PTSD. Journal of Traumatic Stress 2008 21 530–539. (doi:10.1002/jts.20372)